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Abstract 
Purpose: Systemic immune activation has been recently linked to chronic inflammatory disorders of 
the oral cavity, particularly periodontitis. In our study we aimed to determine whether treatment of 
fungus induced oral inflammation, namely denture-related stomatitis (DRS) can affect the activation 
of the systemic immune response. 
Materials and Methods: Peripheral blood from patients with denture-related stomatitis caused by 
Candida albicans infection (n = 15) was collected at three time points: before treatment with nystatin, 
at the end of therapy and 2 months after finishing therapy. Activation of T cells and monocytes was 
assessed by flow cytometry. 
Results: We found that the percentages of peripheral lymphocytes, T cells and their subpopulations, 
as well as monocytes were similar before, immediately following and two months after nystatin 
treatment. Cells expressing early activation marker CD69 and RANTES C-C chemokine receptor type 5 
were significantly increased immediately after treatment and returned to baseline levels after two 
months. Th17 cells, which were implicated in the pathogenesis of DRS remained unchanged. Central 
memory CD4+ subset and intermediate subset of monocytes were lower after therapy and this effect 
was sustained for two months. 
Conclusion: Treatment of denture-related stomatitis does not seem to affect the general state of the 
cellular components of the immune system. Our results suggest a potential proinflammatory effect of 
the antifungal agent, nystatin. Although transient and non intense, this effect might be of particular 
clinical importance, because of relationships between inflammation and certain diseases. Further 
studies are required to clarify this aspect. 
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CCR5 - C-C chemokine receptor type 5 
DRS - denture-related stomatitis 
IL - interleukin 
PBMC – peripheral blood mononuclear cells 
SD - standard deviation 
Th - T helper cells 
Q1 and Q3 - 25th (Q1) and 75th (Q3) percentiles 
Introduction 
Denture-related stomatitis (DRS) is a condition where inflammation of the oral mucous membrane 
occurs beneath a denture. The disease is often known as Candida-associated denture induced 
stomatitis as opportunistic infection with Candida species is associated in about 90% of cases 56. DRS 
is one of the most common diseases in the elderly, affecting up to 70% of patients in the course of life, 
making it an important clinical issue. DRS can negatively influence the patients' quality of life, especially 
in edentulous subjects wearing complete dentures 1,12,23,44. Clinical signs of DRS include erythema and 
swelling of palatal mucosa, sometimes combined with subjective symptoms, such as dysgeusia or 
burning sensation. The aetiology of the DRS is multifactorial 12. Long-term and continuous use of 
dentures and poor denture and oral hygiene habits promote the development of a biofilm, called 
denture plaque, on the surface of the prosthesis 12,44. Candida albicans is component of the normal 
microflora of the human oral cavity 3,13, however, in the presence of a denture and accompanied by 
favourable conditions, including low salivary pH, regular sugar consumption 29 and local immune 
surveillance changes, like decreased salivary antimicrobial enzymes activities and increased 
transforming growth factor β and nitric oxide levels 11, C. albicans becomes an opportunistic pathogen 
leading to infection and DRS. 
It was recently reported that DRS was related to selected systemic co-morbidities, such as vascular 
dysfunction 26. However, the mechanisms linking oral infection and vascular defects are not yet known. 
While in periodontitis systemic activation of the immune system 15,47 is established to be very 
important in mediating increased cardiovascular risk, the extent of systemic activation of immune 
response to DRS is poorly characterized.  
It is known, that the presence of oral fungal infection influences the local immune mechanisms in oral 
cavity in a variety of ways. The mucosal immune response to fungal pathogens include neutrophils as 
major effectors of the innate response, driven by cytokines released from epithelial cells after 
detection of pathogen 46. Epithelial cells also produce β-defensin 2 and chemokine (C-C motif) ligand 
20, which orchestrate dendritic cell recruitment 34. Primed dendritic cells travel to the local lymph 
nodes and present fungal antigens to the T cell, which can differentiate to the T helper (Th): Th1, Th2, 
Th17 and T regulatory (reg) cells. Th17 and Treg cells play a vital role in fighting fungal infection 10,34. 
However, it still remains unclear if these local immune responses are reflected by changes in systemic 
immunity. There are limited studies suggesting that oral Candida infection may impact on the 
peripheral blood mononuclear cells (PBMC) state, as measured by levels of cytokines produced in vitro 
in response to Candida antigens 36,43. The existence of changes in peripheral blood populations that 
are known to be related to systemic chronic inflammation such as CD16+ monocytes 22,49 or activated 
T cells is not known. 
The relationship between oral Candida albicans infection and the systemic inflammatory response has 
not yet been studied. The aim of this study therefore was to determine, whether the treatment of local 
inflammation caused by denture-related stomatitis influenced the systemic immune response as 
measured in activation of peripheral blood immune cells. 
 
 Methods 
The study was independently reviewed and approved by local ethics committee of Jagiellonian 
University. Written informed consent was obtained from all patients and study was conducted in 
accordance with the Declaration of Helsinki. This study has been registered in ClinicalTrials.gov 
(identification no. NCT02166450).  
Patients and clinical evaluation: Patients (n = 15) using acrylic dental prosthesis for at least 6 months 
presenting with clinical signs of DRS such as: erythema, swelling, discomfort and pain in the palatal 
area were recruited. DRS was graded clinically according to Newton's classification scale. Swabs from 
the inflamed area have been taken for the routine microbiological laboratory diagnostic tests for 
Candida species presence to confirm the clinical diagnosis. Swabs were taken from the hard palate 
(between the second and third palatal fold), after an overnight fast and after at least 6 hours of denture 
wear, without cleaning, use of adhesives or rinsing the mouth with disinfectants. Patients were 
recruited when clinical symptoms were confirmed with microbiological culture. In patients with teeth 
present, a periodontal examination was carried out to exclude patients with periodontitis (patients 
excluded if periodontal pocket depths ≥4 mm were identified). Exclusion criteria included also acute 
inflammatory disorders other than DRS, neoplastic disease relapses or chemotherapy courses less than 
5 years before the enrolment, using antibiotics in the previous 4 weeks or anti-inflammatory drugs 
(steroids and non-steroidal, excluding aspirin in doses less than 80 mg) in the previous 2 months prior 
to enrolment. Patients with a history of myocardial infarction, acute coronary incidents, vascular 
inflammation, chronic haematological disorders and immunodeficiency or major medication changes 
in the 5 weeks prior to enrolment, or during the study were also excluded. Patients were recruited 
consecutively and all subjects, who agreed to participate in the study and completed three study visits 
were included in the analysis. 
Patients were referred for treatment of fungal infections, which included application of nystatin 
(100 000 IU) every 6 h for 2 weeks on the mucosal surface of the dentures. Denture that had been 
used for more than 5 years were replaced. In this case the patient was applying nystatin during first 
week on the old denture and during second week on the new denture. If the denture was new and did 
not require replacement, patients were advised to soak the denture in a solution of CoregaTM tablets 
as the daily care, in accordance with the manufacturer's instructions. Blood samples were collected 
from all patients during three visits: the first sample was collected before introducing treatment 
regimen (visit 1), the second immediately after treatment to assess direct influence of therapy (visit 
2), and the third sample was taken 2 months after completion of treatment to assess longer-term 
effects of termination of infection (visit 3).  
Information about systemic risk factors of DRS such as diabetes (fasting glucose level ≥7 mmol/L or 
HbA1c >6.5% or current treatment with insulin or oral hypoglycemic agents), and smoking (current or 
within last 6 months) were based on patient medical records and detailed patient history collected 
during first visit. Definition of clinical risk factors was based on Perk et. al. 38  
Cytometric analysis: Blood samples were collected in EDTA containing tubes (Becton Dickinson (BD), 
Franklin Lakes, NJ, USA). PBMC were isolated using Lymphocyte Separation Medium LSM 1077 (PAA 
Laboratories GmbH, Pasching, Austria). After isolation cells were washed twice with phosphate-
buffered saline with heat inactivated 1% fetal bovine serum (Gibco, Life Technologies, Carlsbad, CA, 
USA) and then incubated for 20 minutes at 4°C with fluorescently labelled monoclonal antibodies (BD 
Pharmingen, San Diego, CA, USA). After washing, cells were re-suspended in phosphate-buffered saline 
with 1% fetal bovine serum and studied on a FACS Canto II or FACS Verse cytometer (BD Bioscences, 
San Jose, CA, USA). Results were analyzed using FlowJo vX software (FLOWJO LCC Data Analysis 
Software, Ashland, OR, USA).  
Lymphocytes were identified among PBMC on FSC/SSC scatter plots and T cell presence was confirmed 
by CD3 staining. Percentages of naive (CD45RA+) and memory (CD45RO+) and CD4+ and CD8+ T cells 
were assessed, as well as presence of surface activation markers in these subpopulations. Monocytes 
were also identified on FSC/SSC scatter plots with confirmation of CD14/HLA-DR staining. Three main 
populations were assessed among monocytes: CD14highCD16-, CD14dimCD16+ and CD14highCD16+. 
The following monoclonal antibodies were used: anti-CD3-PerCP (clone SK7), anti-
CD45RA/CD45RO/CD3/CD4 BD Multitest™, anti-CD4-APC (clone RPA-T4), anti-CD4-PeCy7 (clone SK3), 
anti-CD8-APCH7 (clone SK1), anti-CCR7-PECy7 (clone 3D12), anti-CCR5-PE (2D7/CCR5), anti-CD69-FITC 
(clone FN50), anti-CD25-PE (clone MA-251), anti-CD28-APC (clone CD28.2), anti-CD14-APCH7 (clone 
MⱷP9), anti-HLA-DR-PeCy7 (clone L243), anti-CD16-PE (clone 3G8). Because of technical reasons, it 
was impossible to perform monocyte analysis in one DRS patient. 
Intracellular staining: Intracellular staining was performed in the subgroup of 10 DRS patients. 
Cytokine production by T cells was assessed after 4-hour incubation of PBMC in RPMI medium 1640 
(Gibco, Life Technologies, Carlsbad, CA, USA) with 10% fetal bovine serum (Gibco, Life Technologies, 
Carlsbad, CA, USA), gentamycin and L-glutamine (Sigma, Saint Louis, MO, USA) with stimulation with 
Leukocyte Activation Cocktail with BD GolgiPlug (BD Pharmingen, San Diego, CA, USA). After 20 
minutes on ice staining for cell surface markers (CD3, CD4 and CD8; procedure, suppliers and clones 
presented above), cells were washed with phosphate-buffered saline with heat inactivated 1% fetal 
bovine serum. Cells were permeabilized (20 minutes, on ice) (BD Cytofix/Cytoperm, Fixation and 
Permeabilization Solution, BD Pharmingen, San Diego, CA, USA) and, after washing with BD PermWash 
Buffer (BD Pharmingen, San Diego, CA, USA), stained for intracellular cytokines for 20 minutes on ice. 
Then the cells were washed again with BD PermWash Buffer, resuspended in phosphate-buffered 
saline with 1% fetal bovine serum and studied, as described for extracellular staining procedure.  
The following monoclonal antibodies were used in intracellular staining procedure: anti-IL-17-PE (clone 
N49-653), anti-IL-4-PE (clone 8D4-8), anti-TNFα-FITC (clone MAb11) and anti-IFNγ-FITC (clone B27). 
Non-specific staining with isotype-matched control monoclonal antibodies was used (PE Mouse IgG1κ 
Isotype Control, clone MOPC-21 and FITC Mouse IgG1κ Isotype Control, clone MOPC-21). All antibodies 
were from BD Pharmingen, San Diego, CA, USA. 
Statistical analysis: Assessment of normality of distribution for all continuous variables was conducted 
using the Shapiro-Wilk test. Variables whose distributions were not consistent with a normal 
distribution are presented as median and 25th (Q1); 75th (Q3) percentiles and values for subsequent 
visits were compared by Friedman test, with post-hoc analysis in case of detecting significance. 
Variables with normal distribution are presented as mean ± standard deviation (SD). All variables with 
normal distributions described baseline group characteristic and comparison between visits was not 
applicable. Method of presentation of results is given for each variable in the text. Null hypothesis was 
"Treatment of DRS does not influence the percentages of total lymphocytes and T cells in peripheral 
blood of patients with DRS". Values of p < 0,05 were considered statistically significant. All analysis 
were performed with Statsoft Statistica software (StatSoft, Inc., Tulsa, OK, USA). 
 Results 
Study population characteristics: The clinical characteristics of study participants are shown in Table 
1. The subjects were mostly women (n = 14; 93.33%) and elderly (mean±SD age 62.5±6.3). The mean 
BMI was 29.2 (SD 6.1) and 33.3% of patients were current smokers and 33.3% suffered from diabetes 
mellitus. 93.3% of patients were hypertensive, out of which in only 43% hypertension was controlled. 
Most of the screened subjects were edentulous, only 4 subjects were partial dentures users who had 
periodontal examination preformed to exclude any periodontal diseases. Compared to the general 
population, the proportion of females was significantly higher, what is of particular significance, as 
these features are key risk factors for DRS.  
Lymphocyte characterization in peripheral blood of DRS patients after treatment: The percentages 
of total lymphocytes and T cells in PBMC of DRS patients showed no significant differences after 
treatment (Figure 1 upper panel). Similarly no differences were observed in CD4+ and CD8+ T cell 
subsets (Figure 1 lower panel). Treatment of DRS did not seem to affect median percentages of naive 
(CD45RA+; 46.8±14.6, 42.5±13.2 and 44.8±13.3; p = 0.94) and memory (CD45RO+; 41.13±14.6, 
48.72±13.6 and 47.5±13.12; p = 0.63) T cells, however a tendency to decrease the percentage of naive 
and increase the percentage of memory T cells immediately after treatment was observed. 
Consistently, the percentage of central memory (CD45RA-CCR7+) CD4+ T cells was observed to 
decrease after treatment, reaching statistical significance for comparison of first and third visit (Figure 
2). A similar, albeit non significant, trend was observed for CD8+ memory T cell subset. Percentages of 
the naive (CD45RA+CCR7+) and effector memory (CD45RA-CCR7-) T cells from both, CD4+ and CD8+ 
populations, did not show any differences during all three visits (Figure 2). 
Lymphocyte activation in peripheral blood of DRS patients after treatment: Interestingly, we found 
that the median percentages of cells with expression of early activation marker - CD69 in CD3+ cells 
were significantly higher immediately after treatment and returned to baseline level after 2 months, 
reaching statistical significance for comparison of first and second and first and third visit, and in CD8+ 
subset with differences between first and second visit (Figure 3A). In the CD4+ CD69+ subset as well 
as in subpopulation of cells expressing late activation marker CD25 and with high expression of this 
marker such pattern was not observed (Figure 3 A, B). What is more, the median percentages of T cells 
expressing C-C chemokine receptor type 5 (CCR5), the receptor for the chemokine RANTES, in DRS 
patients were also significantly different between subsequent visits. This percentage increased 
immediately after treatment and returned to baseline level after 2 months, reaching statistical 
significance for comparison of 2nd and 3rd visit (Figure 4). The same trend, with significant difference 
between last two visits, was observed for CCR5-expressing CD4+ and CD8+ subsets, in contrast with 
percentages of CD4+ and CD8+ CD28null subsets, which were similar during consequent visits (Figure 
4). 
T cell cytokine production after treatment of DRS: To investigate whether DRS treatment influence 
major proinflammatory cytokine production in peripheral blood T cells, we performed intracellular 
staining in the subgroup of 10 patients. We did not observe changes of percentage of T cell subsets 
producing intracellular IL-17, IL-4, tumour necrosis factors alpha or interferon gamma during 
subsequent visits (Figure 5). 
Monocyte characteristics in the peripheral blood of DRS patients after treatment: We found that 
there were no statistically significant differences in the percentage of monocytes present in the 
peripheral blood of patients during subsequent visits (Figure 6, upper panel). As peripheral blood 
monocyte subpopulation changes might also reflect systemic immune status in chronic inflammation, 
we next analysed monocyte subsets based on CD14+ and CD16+ expression. We observed, that the 
percentage of classical CD14highCD16- subset of monocytes decreased immediately after treatment 
and lower level sustained two months after treatment. The percentage of intermediate 
CD14highCD16+ monocytes significantly increase after treatment, while non-classical CD14dimCD16+ 
subset do not show significant changes during subsequent visits. (Figure 6 lower panel). 
 
Discussion 
DRS is one of the most common oral diseases among elderly denture wearers 12,23, especially among 
women 12, smokers and diabetic patients 6. These epidemiological facts are reflected by population 
structure in the presented study. The vast majority of recruited patients were female, while smokers 
and diabetics consisted of as much as one third of study population each. These numbers are high 
compared to the general population, since 13.6% of diabetics among older adults were reported for 
Germany 7 or 4.9% for Switzerland 18 and 8.6% of smokers among elderly women for Europe 25. 
In our study we aimed to describe the changes in activation of immune system mechanisms evoked by 
treatment of Candida infection in denture-related stomatitis. Since DRS is a clinical issue of increasing 
importance due to the ageing of population, detection of any association with activation of not only 
local, but also systemic immunity, is of growing relevance.  
Since our experiments are performed in relatively small number of patients, our results should be 
considered preliminary. A potential weakness of our study is lack of a control group of the patients 
who did not undergo DRS treatment. This was caused by the fact that the local ethics committee 
considered it inappropriate to leave patients untreated for the duration of the study. However, we 
believe that it is very unlikely that we would have observed any changes in untreated patients as the 
infection is long lasting and well established. This paper represents a significant contribution to the 
current understanding of the systemic, cellular immune response to the presence of oral inflammation 
related to the DRS as there is currently very little published data in this area. One should also bear in 
mind that over 90% of our study group were women, which, although consistent with epidemiology of 
DRS, might hinder translation of the results to the general population. Because of the preliminary 
character of this study, the sample size was predefined without estimating the minimum sample size. 
Such calculations require information about the extent of the measured trait variability in the 
population. To assess sample size in the methodologically correct way, it should be estimated on the 
basis of the previous scientific data. In our case, in the absence of other studies on peripheral activation 
of cellular components of the immune system in relation to the DRS, it correct and reliable calculations 
of minimum sample size were significantly impeded. 
Activation of immune mechanisms in other oral diseases, namely periodontitis, has been observed 
previously, as elevated levels of C-reactive protein in periodontal patients have been reported 2. This 
association was further confirmed by showing that C-reactive protein levels are lowered after 
periodontal treatment 8,39. Since the DRS shares certain features with periodontal disease, such as the 
presence of chronic local inflammation and involvement of the microorganisms 15, it can be 
hypothesised that there will be a similar effect on the systemic immune mechanisms. A recently 
published study has shown an association between DRS and vascular dysfunction 26, which was also 
observed for periodontitis 8,39. This finding seems to support this theory, however common risk factors 
for oral and vascular diseases might confound interpretation of these results. The mechanisms of 
association between periodontitis and vascular diseases are not clearly defined, but are most likely 
dependent on the systemic inflammatory response, involving increased levels of IL-6, C-reactive 
protein, tumour necrosis factor-α and other cytokines, which accompanies periodontitis 35,50. Cellular 
immunity is also activated in periodontitis, including monocyte subpopulation shifts, as well as T cell 
activation with overproduction of interferon gamma and IL-17 5. We therefore measured the impact 
of the treatment of oral fungal infection (DRS) on systemic features of T cells and monocytes activation 
in the short and medium term (2 months). 
Contrary to our hypothesis, we did not observe any in the percentages of lymphocytes and T cells 
present in the peripheral blood of DRS patients in comparison to baseline values after treatment of 
DRS. The same observation was also true for CD4+ and CD8+ T cell subsets. The lack of differences in 
CD4+ T cell subset was the most surprising as this lymphocyte subset is thought to be of great 
importance in Candida immunity 53. However, studies postulating pronounced role of CD4+ T cells in 
candidiasis have been performed mostly in immunocompromised individuals, while in our study 
population immune functions were not suppressed. It is therefore probable that the immune response 
may present different characteristics.  
We studied naive (CD45RA+), memory (CD45RO+) and CD28null T cells subsets, because asymptomatic 
DRS is able to persist untreated for long periods of time and it is possible that such persistent infection 
may provoking continuous immune activation accelerating senescence of CD8+ T cells marked by loss 
of CD28 marker 52. However, we observed changes in percentage of central memory (CD45RA-CCR7+) 
CD4+ T cells, which seem to decrease after treatment. These cells take part in immune response to the 
known pathogen and readily proliferate and differentiate to effector cells in response to antigenic 
stimulation 30,45, so after depleting of antigen source by defeating of chronic Candida infection, their 
amount decrease, reaching lower, stable levels. 
CCR5 gene expression was shown to be enhanced in peripheral blood monocytes stimulated with C. 
albicans in vitro 20 and PBMC were shown to secrete RANTES in response to the presence of C. albicans 
17. We therefore studied the expression of the chemokine RANTES receptor - CCR5 on T cells. We 
observed similar pattern of CCR5 expression on the whole population of T cells and its particular 
subsets - CD4+ and CD8+. Lower expression was observed after 2 months after finishing the treatment, 
preceded by significant increase immediately after therapy. CCR5 is a marker of Th1 immune response 
and its ligand - RANTES leads immune cells to the site of inflammation. Resolution of DRS inflammation 
leads to a decreased amount of CCR5+ cells, and its initial increase might be related to the local effects 
of nystatin, including disruption of fungal cell integrity leading to enhanced exposure of its antigens 
and induction of proinflammatory IL-1β production 4,41, similarly to described later in this text 
intermediate monocyte subpopulation.  
Consistently, we observed an increase in the percentage of CD69+ T cells and CD8+, but not CD4+, 
immediately after treatment, with a tendency to decrease 2 months after treatment which was 
statistically significant for the whole T cell population. Lower CD69 expression in response to Candida 
stimulus between CD4+ and CD4- cells have been described before and reported percentages (1.5% 
and 10% for CD4+ and CD4- subsets, respectively) are consistent with our study 28. CD69 is expressed 
on lymphocytes rapidly after activation and thus CD69 is known as marker of early lymphocyte 
activation. Therefore, it may seem surprising that the percentage of CD69 expressing cells increase 
after therapy, which lead to the resolving of inflammation. One possible explanation could be 
stimulating effects of nystatin on T cell activation as described for CCR5+ cells 4,41. Another theory relies 
on the fact that CD69 may be implicated in memory T cell formation 27 and probably participate in the 
formation of immune memory after resolving of the infection.  
DRS presence probably influences cytokine production by peripheral immune cells, as suggested by in 
vitro production of IL-2 by mononuclear blood cells of DRS patients in response to the Candida albicans 
43 and high levels of IL-6 and tumour necrosis factors alpha observed in serum of DRS patients 40. In 
contrast to these reports, we did not observe significant changes in production of intracellular 
proinflammatory cytokines, including IL-4, IL-17, tumour necrosis factors alpha or interferon gamma 
by T cell subsets after treatment of DRS. Our results are consistent with studies reporting no difference 
in cytokine concentration in saliva of DRS and healthy subjects 24. Although differences in IL-17 
production by CD4 T cells did not reach significance, they were close to it with p value of 0.061, pointing 
to a possible trend toward lowering IL-17 levels during subsequent study visits. Since the Th17 
response, in which IL-17 is involved, is reported to be of particular importance in defence against fungal 
pathogens 10,34, it is possible that resolving the infection is followed by a decrease in IL-17 production. 
It is plausible that with larger study group, these differences would reach significance. 
We also compared the amount of monocytes and their subpopulations, since these cells and their 
differentiated form - macrophages are elements of the first line of immunologic defence against an 
invading pathogen. Resolution of local inflammation in the oral cavity after treatment of DRS, was not 
associated with changes in percentage of monocytes. However, monocytes are very well known to 
play important role in inflammatory diseases such as rheumatoid arthritis or atherosclerosis 16,21. It 
appears that especially CD16+ subsets are vital and their role in inflammatory conditions were 
described previously in end stage renal disease and in active rheumatoid arthritis 19,21. Changes in 
monocyte subpopulations are visible even at a very early stage of disease 22, with increased amount of 
intermediate CD14highCD16+ and decreased amount of non-classical (CD14dimCD16+) monocytes. It 
is particularly interesting that we observed a reduction in the amount of classical CD14highCD16- and 
an increase in the amount of intermediate CD14highCD16+ monocyte subpopulations immediately 
after treatment and altered amount of these cells was observed to be sustained for at least two 
months. Classical monocyte subset are suggested as a potent inducer of Th17 immune response 
against Candida albicans 48. This type of immune response is now considered vital in combating fungal 
infections 37. After successful DRS therapy linked with reduction in numbers of Candida cells there was 
a reduction in CD14highCD16- monocytes indicating that induction of immune response was no longer 
present. The increase in intermediate monocyte subpopulation after therapy might be considered as 
surprising considering the proinflammatory and proatherogenic character of these cells 54, as well as 
an increase in CD14+CD16+ monocyte subset in periodontal disease 32. The potential explanation of 
this observation includes two factors. Polyene macrolides antifungal drugs, such as nystatin, cooperate 
with host immune defence in clearance of the pathogen. They affect fungal cells directly by disrupting 
cell integrity 42 providing more ligands for host receptors involved in immune activation, such as 
pattern recognition receptors, thus transiently enhancing local inflammation. Although nystatin is 
considered as acting only topically and not being absorbed through skin and gastrointestinal tract, it is 
also known to induce proinflammatory IL-1β production 4,41. Mechanism of this activation involve Toll-
like receptor 2 41, which is also present on immune cells in oral mucosa 9,34. It is possible, that these 
two processes temporarily enhance inflammation in treated area. Intermediate subset of monocytes 
are known to be increased in other inflammatory conditions 19,21, and this may also be the case in DRS. 
To conclude, the main observation of our work is the lack of the evidence of a systemic cellular 
response to the treatment of oral C. albicans infection. This is in spite the fact that there is evidence 
of very complex immune mechanisms involved in defence against oral fungal infection including 
various cell types 33,46,51,53. While this is in contrast to our hypothesis, we believe that this is a very 
important consideration for interpretation of some of systemic features of DRS. Simultaneously, our 
results might point to the possible, systemic inflammatory response to the topical application of 
polyene macrolide antifungal agent - nystatin. Although transient and non intense, such effect is 
mechanistically plausible and may comprise a clinically important finding. DRS patients are usually 
elderly and, as such, more susceptible to changes in immune function. Since IL-1β is a cytokine with 
proinflammatory characteristics, even low but unphysiologically induced production in susceptible 
population might influence the risk of inflammatory diseases, such as atherosclerosis 16,31 or 
rheumatoid arthritis 55. Our previous study, where we described dysfunction of the vascular 
endothelium in DRS patients 26, may further point to the importance of this aspect, since endothelial 
dysfunction is known to precede the development of atherosclerosis 14 and its complications, such as 
hypertension. 
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Table 1. Clinical characteristics of studied group. Data are presented as mean(SD) or n(%). 
 DRS patients 
Number of patients 15 
Age [years] 62,5 (6,3) 
BMI 29,1 (6,1) 
Gender (M:F) 1 : 14 
Current smoking 5 (33,3%) 
Diabetes 5 (33,3%) 
Coronary artery disease 6 (40%) 
Controlled hypertension 6 (40%) 
Untreated hypertension 8 (53,3%) 
Newton's classification scale 
type I 
type II 
type III 
 
0 
14 
1 
BMI - body mass index; M - males; F - females  
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Figure legends:  
Figure 1. Lymphocytes and their basic subpopulations in DRS patients treated with nystatin. 
Comparison of lymphocytes and T cells counts and basic T cell subpopulations: CD4+ and CD8+ in DRS 
patients before starting nystatin therapy (visit 1), immediately after finishing it (visit 2) and two months 
after therapy completion (visit 3). Lymphocyte subpopulation was measured in peripheral blood by 
flow cytometry. Results presented as median (Q1; Q2).  
Figure 2. Subsets of the naive, effector and central memory CD4+ and CD8+ T cells present in 
peripheral blood of DRS patients treated with nystatin. Counts of the naive (CD45RA+CCR7+), effector 
(CD45RA-CCR7-) and central memory (CD45RA-CCR7+) T cells before starting nystatin therapy (visit 1), 
immediately after finishing it (visit 2) and two months after therapy completion (visit 3) were assessed 
by flow cytometry. Results presented as median (Q1; Q2). ¶ - p < 0,05 for comparison of 1st and 3rd 
visit. 
Figure 3. A. Comparison of percentage of activated T cells of DRS patients treated with nystatin in 
CD4 and CD8 subset of lymphocytes. Expression of early activation marker (CD69) and late activation 
marker (CD25) were studied in peripheral blood by flow cytometry before starting nystatin therapy 
(visit 1), immediately after finishig it (visit 2) and two months after therapy completion (visit 3). Data 
are presented as % of cells expressing individual marker. Results presented as median (Q1; Q2). * - p 
< 0,05 for comparison of 1st and 2nd visit; ¶ - p < 0,05 for comparison of 1st and 3rd visit. B. Presence 
of CD25high T cells in treated DRS patients. Percentage of CD25high T cell subsets were assessed 
before starting nystatin therapy (visit 1), immediately after finishing it (visit 2) and two months after 
therapy completion (visit 3). Results presented as median (Q1; Q2).  
Figure 4. Comparison of percentage of CCR5+ and of CD28null T cells subsets in DRS patients 
treated with nystatin. Chemokine RANTES receptor CCR5 in CD4 and CD8 subsets and prevalence of 
CD4+ CD28null and CD8+CD28null cells were studied in peripheral blood by flow cytometry before 
starting nystatin therapy (visit 1), immediately after finishing it (visit 2) and two months after therapy 
completion (visit 3). Data are presented as median (Q1;Q2) % of cells expressing individual marker. * 
- p < 0,05 for comparison of 1st and 2nd visit; # - p < 0,05 for comparison of 2nd and 3rd visit. 
Figure 5. Results of intracellular staining of CD4+ and CD8+ T cell subsets in peripheral blood of DRS 
patients treated with nystatin. Percentage of cells producing IL-4, IL-17, TNFα or IFNγ was assessed 
by flow cytometry before starting nystatin therapy (visit 1), immediately after finishing it (visit 2) and 
two months after therapy completion (visit 3). Results presented as median (Q1; Q2); n = 10. 
Figure 6. Comparison of monocytes and monocyte subsets in peripheral blood of DRS patients 
treated with nystatin. Counts of the presented subpopulations were assessed by flow cytometry 
before starting nystatin therapy (visit 1), immediately after finishing it (visit 2) and two months after 
therapy completion (visit 3). Results presented as median (Q1; Q2); n = 14. * - p < 0,05 for comparison 
of 1st and 2nd visit; ¶ - p < 0,05 for comparison of 1st and 3rd visit. 
  
 
